Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Global Forecast 2024-2030

Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Global Forecast 2024-2030


The Intravenous Immunoglobulin Market size was estimated at USD 1.25 billion in 2023 and expected to reach USD 1.33 billion in 2024, at a CAGR 6.92% to reach USD 1.99 billion by 2030.

Global Intravenous Immunoglobulin Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Intravenous Immunoglobulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Intravenous Immunoglobulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, Inc., Baxter International, Inc., Bayer HealthCare LLC, Biotest AG by Grifols S.A., CSL Behring, Johnson & Johnson Services, Inc., Kedrion S.p.A., LFB Biotechnologies, Octapharma AG, and Option Care Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Intravenous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication
Primary Immunodeficiency

Secondary Immunodeficiency

Form
Liquid IVIG

Lyophilized IVIG

End-User
Homecare Facilities

Hospitals & Clinics

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Intravenous Immunoglobulin Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Intravenous Immunoglobulin Market?
3. What are the technology trends and regulatory frameworks in the Intravenous Immunoglobulin Market?
4. What is the market share of the leading vendors in the Intravenous Immunoglobulin Market?
5. Which modes and strategic moves are suitable for entering the Intravenous Immunoglobulin Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Intravenous Immunoglobulin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
5.1.1.2. Significant rise in geriatric population and number of hemophilic patients
5.1.1.3. Rising use of off-label indications in intravenous immunoglobulin products
5.1.2. Restraints
5.1.2.1. Stringent government regulations toward the use of intravenous immunoglobulin products
5.1.3. Opportunities
5.1.3.1. Emergence of improved technologies in immunoglobulin production
5.1.3.2. Increasing number of intravenous immunoglobulin product approvals
5.1.4. Challenges
5.1.4.1. High risk of side effects associated with intravenous immunoglobulin products
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Intravenous Immunoglobulin Market, by Indication
6.1. Introduction
6.2. Primary Immunodeficiency
6.3. Secondary Immunodeficiency
7. Intravenous Immunoglobulin Market, by Form
7.1. Introduction
7.2. Liquid IVIG
7.3. Lyophilized IVIG
8. Intravenous Immunoglobulin Market, by End-User
8.1. Introduction
8.2. Homecare Facilities
8.3. Hospitals & Clinics
9. Americas Intravenous Immunoglobulin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Intravenous Immunoglobulin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.
10. South Korea
10.
11. Taiwan
10.
12. Thailand
10.
13. Vietnam
11. Europe, Middle East & Africa Intravenous Immunoglobulin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.
10. Nigeria
11.
11. Norway
11.
12. Poland
11.
13. Qatar
11.
14. Russia
11.
15. Saudi Arabia
11.
16. South Africa
11.
17. Spain
11.
18. Sweden
11.
19. Switzerland
11.
20. Turkey
11.
21. United Arab Emirates
11.
22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. ADMA Biologics, Inc.
13.1.2. Baxter International, Inc.
13.1.3. Bayer HealthCare LLC
13.1.4. Biotest AG by Grifols S.A.
13.1.5. CSL Behring
13.1.6. Johnson & Johnson Services, Inc.
13.1.7. Kedrion S.p.A.
13.1.8. LFB Biotechnologies
13.1.9. Octapharma AG
13.1.
10. Option Care Health, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
FIGURE 3. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INTRAVENOUS IMMUNOGLOBULIN MARKET DYNAMICS
FIGURE 7. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
FIGURE 10. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings